ArticleWellcome open research2018
Ideation and implementation of an open science drug discovery business model - M4K Pharma.
Article in Wellcome open research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The prevalence of post-NDA drug patents and their relationship to the timing of generic approval.Nature biotechnology · 2024Article
- Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases.Orphanet journal of rare diseases · 2022Article
- Target 2035 - update on the quest for a probe for every protein.RSC medicinal chemistry · 2022Article
- Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging ofACS medicinal chemistry letters · 2021Article
- There is no market for new antibiotics: this allows an open approach to research and development.Wellcome open research · 2021Article
- Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.Journal of medicinal chemistry · 2020Article
- Six Laws of Open Source Drug Discovery.ChemMedChem · 2019Article
- Fostering open collaboration in drug development for paediatric brain tumours.Biochemical Society transactions · 2019Review
- Open laboratory notebooks: good for science, good for society, good for scientists.F1000Research · 2019Article
- Open science approaches to COVID-19.F1000ResearchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
M4K Pharma was incorporated to launch an open science drug discovery program that relies on regulatory exclusivity as its primary intellectual property and commercial asset, in lieu of patents.In many cases and in key markets, using regulatory exclusivity can provide equivalent commercial protection to patents, while also being compatible with open science. The model is proving attractive to government, foundation and individual funders, who collectively have different expectations for returns on investment compared with biotech, pharmaceutical companies, or venture capital investors.In the absence of these investor-driven requirements for returns, it should be possible to commercialize therapeutics at affordable prices.M4K is piloting this open science business model in a rare paediatric brain tumour, but there is no reason it should not be more widely applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.